Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone843-900-3201
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.90 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.15. The biopharmaceutical company earned $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. AEterna Zentaris had a negative return on equity of 1,428.66% and a negative net margin of 536.79%. View AEterna Zentaris' Earnings History.
When is AEterna Zentaris' next earnings date?
What price target have analysts set for AEZS?
2 brokerages have issued 12-month price targets for AEterna Zentaris' shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate AEterna Zentaris' share price to reach $2.50 in the next twelve months. This suggests a possible upside of 131.5% from the stock's current price. View Analyst Price Targets for AEterna Zentaris.
What is the consensus analysts' recommendation for AEterna Zentaris?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris.
What are Wall Street analysts saying about AEterna Zentaris stock?
Here are some recent quotes from research analysts about AEterna Zentaris stock:
- 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (10/8/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams." (8/15/2019)
Has AEterna Zentaris been receiving favorable news coverage?
News coverage about AEZS stock has been trending somewhat positive on Monday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AEterna Zentaris earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for AEterna Zentaris.
Are investors shorting AEterna Zentaris?
AEterna Zentaris saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 406,500 shares, a drop of 42.7% from the August 30th total of 709,100 shares. Based on an average daily trading volume, of 134,300 shares, the short-interest ratio is currently 3.0 days. Currently, 2.4% of the shares of the company are sold short. View AEterna Zentaris' Current Options Chain.
Who are some of AEterna Zentaris' key competitors?
Some companies that are related to AEterna Zentaris include BioXcel Therapeutics (BTAI), NeuBase Therapeutics (NBSE), Galmed Pharmaceuticals (GLMD), Verastem (VSTM), Aquestive Therapeutics (AQST), Vaccinex (VCNX), Humanigen (HGEN), Cumberland Pharmaceuticals (CPIX), Mersana Therapeutics (MRSN), Neoleukin Therapeutics (NLTX), vTv Therapeutics (VTVT), Lipocine (LPCN), Entasis Therapeutics (ETTX), Checkpoint Therapeutics (CKPT) and Aravive (ARAV).
What other stocks do shareholders of AEterna Zentaris own?
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- Mr. Michael V. Ward, Pres & CEO (Age 62)
- Ms. Leslie Auld, Sr. VP & CFO
- Mr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.
- Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
- Mr. Olaf Althaus, GM & MD
How do I buy shares of AEterna Zentaris?
Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AEterna Zentaris' stock price today?
One share of AEZS stock can currently be purchased for approximately $1.08.
How big of a company is AEterna Zentaris?
AEterna Zentaris has a market capitalization of $21.56 million and generates $26.90 million in revenue each year. The biopharmaceutical company earns $4.19 million in net income (profit) each year or $0.25 on an earnings per share basis. View Additional Information About AEterna Zentaris.
What is AEterna Zentaris' official website?
How can I contact AEterna Zentaris?
AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3201 or via email at [email protected]
MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
